Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03985527 · ClinicalTrials.gov registry record · NA

Janus Feasibility Study

A NA study of Sleep Apnea Syndromes, sponsored by Respicardia.

Completed
Registry status
NA
Development phase
29
Enrollment target
3
Study locations

NCT03985527 is a NA study of Sleep Apnea Syndromes that has completed, run by Respicardia. The registered enrollment target is 29 participants, below the 322-participant average among 8 other Sleep Apnea Syndromes trials with a reported enrollment target (91% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03985527, a NA study of Sleep Apnea Syndromes, has completed, sponsored by Respicardia.

COMPLETED
Registry status
NA
Development phase
29 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this feasibility study is to assess whether an alternative transvenous lead location affects respiration and airway physiology during a commercial remedē® System or commercial transvenous cardiac device (de novo pacemaker or implantable cardiac defibrillator) implant procedure.

Conditions Studied

Interventions

  • DEVICE Transvenous nerve stimulation

Study Locations (3)

North Carolina

  • Novant Health Forsyth Medical Center - Winston-Salem

Ohio

  • The Ohio State University Wexner Medical Center - Columbus

Pennsylvania

  • Bryn Mawr Medical Specialists Association - Bryn Mawr

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 2020-01-09
Est. Completion 2025-12-12
Phase NA

Sponsor

Respicardia

8 total trials

What the Registry Record Tells You About NCT03985527

The ClinicalTrials.gov registry entry for NCT03985527 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 322-participant average among 8 other Sleep Apnea Syndromes trials with a reported enrollment target (91% lower). The listed sponsor is Respicardia, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Sleep Apnea Syndromes appearing as the primary indexed condition, and to 1 intervention - of which Transvenous nerve stimulation is the first listed.

NCT03985527 reports 3 study locations spanning 3 distinct geographic areas - top geographies include North Carolina, Ohio, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT03985527 about?

NCT03985527 is a clinical study titled "Janus Feasibility Study". The purpose of this feasibility study is to assess whether an alternative transvenous lead location affects respiration and airway physiology during a commercial remedē® System or commercial transvenous cardiac device (de novo pacemaker or implantable cardiac defibrillator) implant procedure.

What is the current status of trial NCT03985527?

This trial is currently completed. It is a NA study. The enrollment target is 29 participants. The study started on 2020-01-09. Estimated completion is 2025-12-12.

What conditions does trial NCT03985527 study?

This clinical trial studies the following conditions: Sleep Apnea Syndromes.

What interventions are being tested in trial NCT03985527?

The interventions under investigation include: Transvenous nerve stimulation (DEVICE).

Who is sponsoring clinical trial NCT03985527?

This trial is sponsored by Respicardia, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03985527 being conducted?

This trial has 3 study locations across North Carolina, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sleep Apnea Syndromes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.